Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Abdullah Esmail

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2337-8351; OpenAlex author ID A5012528261. Sources: OpenAlex.

Their work

Papers
8 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2024: 3 papers · 2025: 2 papers · 2026: 3 papers

Papers 8

  1. Excellent Survival Outcome in a Patient Receiving NALIRIFOX for Metastatic Pancreatic Adenocarcinoma: A Case Report. Co-author DOI 10.32604/or.2026.083192↗
  2. NALIRIFOX versus FOLFIRINOX: reconstructed individual patient data meta-analysis of efficacy and safety in first-line treatment of unresectable or metastatic p… Co-author DOI 10.3389/fonc.2026.1902839↗
  3. Prognostic Impact of Baseline Circulating Tumor DNA (ctDNA) in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. First author DOI 10.3390/cancers18142286↗
  4. Correlative Analysis of Tumor-Informed Circulating Tumor DNA (ctDNA) and the Survival Outcomes of Patients with Pancreatic Adenocarcinoma. First author DOI 10.3390/biomedicines13051124↗
  5. An 81-Year-Old Geriatric Patient with Metastatic Pancreatic Cancer Demonstrating Excellent Response and Well Tolerance to NALIRIFOX: A Case Report and Literatu… First author DOI 10.3390/reports8020069↗
  6. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. First author DOI 10.1038/s41698-024-00571-4↗
  7. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
  8. Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments. Co-author DOI 10.3389/fonc.2024.1386699↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maen Abdelrahim · 7 shared papers, 2024–2026 · strength 1.78
  2. Bayan Khasawneh · 3 shared papers, 2025–2026 · strength 0.90
  3. Anup Kasi · 2 shared papers, 2024 · strength 0.39
  4. Tahrir Abdelrahim · 1 shared paper, 2026 · strength 0.39
  5. Asem H. Mansour · 1 shared paper, 2026 · strength 0.29
  6. Hikmat Abdel‐Razeq · 1 shared paper, 2026 · strength 0.29
  7. Yuqi Zhang · 1 shared paper, 2025 · strength 0.27
  8. Nestor F. Esnaola · 1 shared paper, 2024 · strength 0.24
  9. Benjamin Adam Weinberg · 1 shared paper, 2024 · strength 0.24
  10. Doaa Bugazia · 1 shared paper, 2024 · strength 0.20
  11. Sreenivasa Rao Chandana · 1 shared paper, 2024 · strength 0.15
  12. Naomi H. Fei · 1 shared paper, 2024 · strength 0.15
  13. Farshid Dayyani · 1 shared paper, 2024 · strength 0.15
  14. Pashtoon Murtaza Kasi · 1 shared paper, 2024 · strength 0.15
  15. Midhun Malla · 1 shared paper, 2024 · strength 0.15
  16. Michael Cecchini · 1 shared paper, 2024 · strength 0.15
  17. Giby V. George · 1 shared paper, 2024 · strength 0.15
  18. Jill Lacy · 1 shared paper, 2024 · strength 0.15
  19. Gregory P. Botta · 1 shared paper, 2024 · strength 0.15
  20. Adham Adel Jurdi · 1 shared paper, 2024 · strength 0.15
  21. Diana L. Hanna · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.